WO2017099329A1 - 소취용 화장품 조성물 및 그 제조방법 - Google Patents
소취용 화장품 조성물 및 그 제조방법 Download PDFInfo
- Publication number
- WO2017099329A1 WO2017099329A1 PCT/KR2016/009071 KR2016009071W WO2017099329A1 WO 2017099329 A1 WO2017099329 A1 WO 2017099329A1 KR 2016009071 W KR2016009071 W KR 2016009071W WO 2017099329 A1 WO2017099329 A1 WO 2017099329A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ratio
- mixed
- cosmetic composition
- silver
- deodorizing
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/20—Halogens; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/24—Phosphorous; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/25—Silicon; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/26—Aluminium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/28—Zirconium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/731—Cellulose; Quaternized cellulose derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- A61K8/8147—Homopolymers or copolymers of acids; Metal or ammonium salts thereof, e.g. crotonic acid, (meth)acrylic acid; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- A61K8/8152—Homopolymers or copolymers of esters, e.g. (meth)acrylic acid esters; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q15/00—Anti-perspirants or body deodorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/413—Nanosized, i.e. having sizes below 100 nm
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/48—Thickener, Thickening system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/77—Perfumes having both deodorant and antibacterial properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/95—Involves in-situ formation or cross-linking of polymers
Definitions
- the present invention relates to a clean gel for antibacterial and antiviral applied to a specific part of the body, and more particularly, to constitute a clean gel composition in which the antimicrobial and antiviral and deodorant active ingredients are combined and excellent antibacterial and antiviral activity and Deodorant cosmetic composition and its manufacture that have deodorant activity and maintain cleanliness of important parts of the body (e.g. genitals), and can effectively prevent sexually transmitted diseases such as gonorrhea and acquired immunodeficiency syndrome (AIDS) It is about a method.
- AIDS acquired immunodeficiency syndrome
- sex is one of the strongest desires among human instincts and one of affection acts in which men and women meet and confirm each other's affection and love by physical contact.
- Contraceptive devices such as condoms, which are easy to use, are used to prevent sexually transmitted diseases, such as AIDS, and to prevent unwanted pregnancy. It is a contraceptive device that is used so much that it can be easily purchased through vending machines in convenience stores and public places.
- the male contraceptive device is manufactured by molding the rubber having excellent elasticity and liquid barrier property into a substantially cylindrical shape to prevent the semen from leaking to the outside or penetrating the external substance into the inside, and as thin as possible to prevent deterioration of feeling. Manufacture.
- the male contraceptive device made of rubber has a large coefficient of friction, it can be easily applied by applying a lubrication aid such as gel on the outer surface thereof, or in some cases, chemically irritating the body of a male or a female. It can also be used to prevent unwanted pregnancy by preventing male semen from entering the woman's uterus during sexual intercourse, and to prevent sexually transmitted diseases such as gonorrhea and acquired immunodeficiency by blocking male genitalia from external substances. It was.
- the male contraceptive device as described above has a tendency to be torn or users to avoid wearing, and thus many cases of preventing sexually transmitted diseases properly, there is an urgent need for special measures for preventing sexually transmitted diseases.
- the present invention is to improve the conventional problems as described above, the object of the present invention is to combine the antibacterial and antiviral and deodorant active ingredients with non-alcoholic, antiseptic and non-toxic, non-irritating and fragrance-free
- the object of the present invention is to combine the antibacterial and antiviral and deodorant active ingredients with non-alcoholic, antiseptic and non-toxic, non-irritating and fragrance-free
- a clean gel composition that can be applied to important areas of the body, it has excellent antibacterial and antiviral activity and deodorant activity during sexual intercourse to maintain cleanliness of the genital area, which is an important part of the body, and to have sex without using contraceptive devices.
- the present invention also provides a deodorizing cosmetic composition and a method for manufacturing the same, which effectively prevents infection of bacteria or viruses against sexually transmitted diseases such as gonorrhea and acquired immunodeficiency syndrome (AIDS), and enables a healthy sex life of men and women.
- AIDS acquired immunodeficiency syndrome
- Deodorant cosmetic composition of the present invention for achieving the above object, 12 to 18 wt% butylene glycol (Butylene Glycol), 7 to 13 wt% glycerin (Glycerin), additive 1.11 in purified water (Aqua) 65 to 79.89 wt% To 5.85 wt%, and the additive is sodium polyacrylate, catalyst, carbomer, inorganic carrier, metal salt, silver precursor, citric acid, hydroxy It is composed of ethyl cellulose (hidroxyethylcellulose).
- the sodium polyacrylate is mixed at a ratio of 1 to 4 wt%
- the catalyst is mixed at a ratio of 0.01 to 0.30 wt%
- the carbomer is at a ratio of 0.01 to 0.30 wt%.
- the inorganic carrier is mixed at a ratio of 0.01 to 0.30 wt%
- the metal salt is mixed at a ratio of 0.01 to 0.30 wt%
- the silver precursor is mixed at a ratio of 0.05 to 0.30 wt%.
- the citric acid is mixed at a ratio of 0.01 to 0.05 wt%
- the hydroxyethyl cellulose is mixed at a ratio of 0.01 to 0.30 wt%.
- the catalyst is at least one selected from the group consisting of ammonia water, ammonium bicarbonate, triethanolamine (Triethanolamine).
- the inorganic carrier is at least one selected from the group consisting of silica, zeolite, and zirconium having an average particle diameter of 100 to 150 nm.
- the metal salt is at least one selected from the group consisting of nitrates, phosphates and carbonates of the metal.
- the silver precursor is at least one selected from the group consisting of silver nitrate, silver nitrite and silver perchlorate.
- the manufacturing method for the deodorizing cosmetic composition of the present invention (a) 12 to 18 wt% of butylene glycol (Butylene Glycol) with respect to purified water (Aqua) 65 to 79.89 wt% Making; (b) 1 to 4 wt% of sodium polyacrylate, 0.01 to 0.30 wt% of catalyst, 0.01 to 0.3 carbomer, as an additive comprising an active ingredient for antibacterial and antiviral and deodorizing in the primary mixture of step (a) 0.30 wt%, inorganic carrier 0.01 to 0.30 wt%, metal salt 0.01 to 0.30 wt%, silver precursor 0.05 to 0.30 wt%, citric acid 0.01 to 0.05 wt%, hydroxyethyl cellulose 0.01 to 0.30 wt% secondary Mixing, but the metal salt and the silver precursor is reacted for 3 to 4 hours at a temperature range of 35 to 38 °C by adding a reducing agent to form a bonding layer on the
- the reducing agent is ascorbic acid or sodium borohydride, 0.1 to 0.5 parts by weight based on 100 parts by weight of the clean gel composite.
- the present invention is to construct a clean gel composition that can be applied to important parts of the body with antibacterial and antiviral and deodorant active ingredients combined with non-alcoholic, antiseptic and nontoxic, non-irritating and fragrance-free, Through this, it has excellent antibacterial and antiviral activity and deodorant activity during sexual intercourse to maintain the cleanliness of the genital organs, and sexually transmitted diseases such as gonorrhea and acquired immunodeficiency syndrome (AIDS) during sexual intercourse without the use of contraceptive devices. While effectively preventing the infection of bacteria and viruses against can be expected the effect of enabling a healthy sex life of men and women.
- AIDS acquired immunodeficiency syndrome
- 1 and 2 are relationship graphs for experiments of time-viability for skin irritation tests in an embodiment of the invention.
- Figure 3 is an experimental graph of the graph pad prism of the inhibitory concentration compared to HIV-1 in the embodiment of the present invention.
- FIG 4 is an experimental graph showing graph pad prisms for the presence of C8166 cell concentration in an embodiment of the invention.
- the terms "comprise” or “having” are intended to indicate that there is a feature, number, step, action, component, part, or combination thereof described in the specification, and one or more other features. It is to be understood that the present invention does not exclude the possibility of the presence or the addition of numbers, steps, operations, components, parts, or combinations thereof.
- Manufacturing method for the deodorizing cosmetic composition according to an embodiment of the present invention is to include the steps of (a), (b), (c).
- step (a) 12 to 18 wt% of butylene glycol, which is a solvent having antimicrobial activity as alcohols, is first mixed with 65 to 79.89 wt% of purified water.
- Step (b) is a secondary mixture of an antimicrobial, antiviral and deodorant active ingredient in the primary mixture of step (a) as a secondary mixture
- the additive is sodium polyacrylate 1 to 4 wt% , 0.01 to 0.30 wt% of catalyst, 0.01 to 0.30 wt% of carbomer, 0.01 to 0.30 wt% of inorganic carrier, 0.01 to 0.30 wt% of metal salt, 0.05 to 0.30 wt% of silver precursor, 0.01 to 0.05 wt% of citric acid, hydroxy Ethyl cellulose is a second mixture of 0.01 to 0.30 wt%, the metal salt and the silver precursor is reacted for 3 to 4 hours at a temperature range of 35 to 38 °C by adding a reducing agent to bind on the surface of the inorganic carrier It is.
- the sodium polyacrylate is a sodium salt of the acrylic acid polymer is a water-soluble thickener, exists in a coil (coil) state, when encountering water (H 2 O) is uncoiled (uncoil) state and COOH group The whole is dissociated into COO ⁇ to maximize the ionic repulsive force to form a viscosity so that the film can be formed when the formulation of the clean gel composition to be obtained in the embodiment of the present invention is applied to the skin.
- the catalyst is selected from at least one selected from the group consisting of ammonia water, ammonium bicarbonate, and triethanolamine, but preferably triethanolamine is used, but is not necessarily limited thereto.
- the carbomer is an acidic polymer compound mainly polymerized with acrylic acid as a thickener, and is configured to increase the viscosity of the clean gel composition to be obtained in an embodiment of the present invention.
- the inorganic carrier is at least one selected from the group consisting of silica, zeolite, and zirconium having an average particle diameter of 100 to 150 nm, but preferably silica is used. It is not necessarily limited to such a thing.
- the silica is prepared by the silica particles having an average particle diameter of 100 to 150nm by stirring the silicon alkoxide in the alcohol solvent for 6 to 7 hours at 35 to 38 °C in the presence of the catalyst, the silica particles thus prepared It is intended to function as a carrier of antibacterial and antiviral components, a deodorizing functional component and a far infrared emitter.
- the particle size of the particles it is important to distribute the particle size of the particles within a certain range. If the particles are less than 100 nm, nanoparticles may penetrate the skin of the human body and cause toxicity. It is because there exists a possibility that surface area of particle
- the alcohol solvent includes methanol, ethanol, propanol and the like, the content of which is used in the content of 700 to 800 parts by weight based on 100 parts by weight of the silicon alkoxide, if the viscosity of the reaction solution is too large or It is not desirable because it is small.
- the reaction time may be carried out for 6 to 7 hours, if less than 6 hours the reaction does not occur sufficiently, if more than 7 hours the non-uniformity of the silica powder particle size distribution due to the production of secondary particles after the production of primary particles It is not preferable because the same problem occurs, the reaction temperature is carried out at 35 °C to 38 °C, if less than 35 °C reaction time is longer, if it exceeds 38 °C problem occurs in the formation of uniform particles to be.
- the silica particles obtained in the above step is mixed in an alcohol solvent with any one metal salt selected from the group consisting of silver precursor and zinc (Zn), magnesium (Mg), calcium (Ca) and copper (Cu), and then a reducing agent. Is added to reduce the silver precursor to form a combined layer of antibacterial and antiviral and deodorant components on the surface of the silica particles together with the metal salt.
- any one metal salt selected from the group consisting of silver precursor and zinc (Zn), magnesium (Mg), calcium (Ca) and copper (Cu)
- the antibacterial and antiviral and deodorizing components of the binding layer forming process is carried out for 3 to 4 hours at 35 to 38 °C in an alcohol solvent so that the silver precursor is reduced and the metal salt is sufficiently bonded to the surface of the silica particles. If the reaction time is less than 3 hours, the reaction does not occur sufficiently and sufficient bonding cannot be achieved. If the reaction time is more than 4 hours, economic efficiency is lowered, which is not preferable.
- Silver nitrate, silver nitrite, silver perchlorate, etc. may be used as the silver precursor, and the metal salt may be nitrate, phosphate, or carbonate of a metal.
- the total amount of the silver precursor and the metal salt mixed in the alcohol solvent is preferably 0.15 to 0.50 wt% based on 100 wt% of the clean gel composition to be obtained in the embodiment of the present invention.
- the antibacterial and antiviral and deodorizing activity is poor due to the inability to form a layer, and when it exceeds 0.50 wt%, too much bonding is caused to the silica particles, which decreases the far-infrared radiation efficiency. not.
- the mixing ratio of the silver precursor and the metal salt is based on weight, and most preferably, the silver precursor is 0.05 to 0.20 wt% and the metal salt is mixed at 0.1 to 0.3 wt%.
- methanol, ethanol, propanol or a mixture thereof may be used, and may be used in a ratio of 2550 to 2650 parts by weight based on 100 parts by weight of the silica particles.
- reducing agent used to reduce the silver precursor conventional reducing agents such as ascorbic acid and sodium borohydride (NaBH 4) may be used, and the content thereof is 100 parts by weight of the silica particles. 0.1 to 0.5 parts by weight may be used.
- silver (Ag) and the metal particle bonding layer are uniformly formed to a thickness of 2 to 5 nm on the surface of the silica particles.
- the antimicrobial and antiviral and deodorant component bonding layer is preferably formed by uniformly bonding silver and metal particles in the form of particles aggregated on the surface of the silica particles.
- the bonding layer covers the entire surface of the silica particles, it is not preferable because it reduces the far-infrared radiation efficacy of the silica particles.
- Silver precursors such as silver nitrate, silver nitrite and silver perchlorate are expensive, and economical is inferior when only a silver precursor is used.
- a relatively inexpensive metal salt such as zinc, magnesium, calcium, copper, etc. with silver, while using only the expensive silver precursor, a simple process at low cost to a deodorizing cosmetic composition having excellent activity It can be manufactured by.
- Deodorizing cosmetic composition prepared according to an embodiment of the present invention was confirmed to have an antifungal activity and air purification function according to far infrared radiation in addition to antibacterial and antiviral activity and deodorant activity.
- the clean gel composition is any one selected from the group consisting of a dispersion medium, preferably alcohol, water, 1,3-butylene glycol, glycerin and polyethylene glycol using a high-speed azi mixer, More preferably, it is dispersed in glycerin, in which case the speed of the azi mixer is preferably adjusted to 100 to 500 rpm. If the speed is less than 100 rpm dispersing is not made well there may be precipitation and discoloration after production of the aqueous composition, if the speed exceeds 500 rpm there is a disadvantage that the energy consumed for the production increases.
- a dispersion medium preferably alcohol, water, 1,3-butylene glycol, glycerin and polyethylene glycol using a high-speed azi mixer, More preferably, it is dispersed in glycerin, in which case the speed of the azi mixer is preferably adjusted to 100 to 500 rpm. If the speed is less than 100 rpm dispersing is not made well there may be precipitation and
- the clean gel composition according to the embodiment of the present invention may further include a fragrance.
- the clean gel composition according to the embodiment of the present invention exhibits a deodorizing effect due to the deodorization effect due to the porosity of silica and the suppression of the odor causing bacteria by the antibacterial component. In addition, it is possible to achieve an excellent deodorizing effect by masking the odor using a fragrance.
- the preferred fragrance is excellent in reverberation, and more preferably, the composition of the base note is enhanced rather than the top note, so that the fragrance is excellent.
- the fragrance may be used in 0.01 to 0.10 wt% with respect to the total composition, but is not necessarily limited to this ratio.
- ethanol and a surfactant may be used together to uniformly distribute the clean gel composition and maintain transparency.
- the content of ethanol used in this case is 5 to 20 wt%, preferably 10 to 15 wt% with respect to the total composition.
- the surfactant is at least 1 to 4 times, preferably 0.1 to 0.5 wt%, of the fragrance used, but the preferred proportion of fragrance, ethanol and surfactant is a uniform distribution and transparency of the composite depending on the fragrance used and the surfactant used. It should be determined in the range to obtain.
- the surfactant cationic, anionic or nonionic surfactants which are commonly used may be used, and preferably anionic or nonionic surfactants, and more preferably anionic surfactants, may be used.
- the clean gel composition according to the embodiment of the present invention may use a concentration adjusting agent, preferably Citric Acid, and the clean gel composition according to the embodiment of the present invention prepared by the above method may be used in a conventional method. It can be formulated into a formulation that is applied to the penis, which is an important part of men.
- a concentration adjusting agent preferably Citric Acid
- BioScience Laboratories, Inc. is located at 1775 South 19th Avenuc Bozeman, MT 59718, at 406-587-5735, at 406-586-7930, or at 406-586-7930. Is www.biosciencelabs.com.
- One product-Test Article No. 1 clean gel (aka; Double S Gel (Lot No. 15730A2), hereinafter referred to as 'experimental product') is a commercially available MTT shelf life (ET-50) Cellular laboratory tests and skin tissue models were used to assess for their own skin inflammation potential.
- ET-50 MTT shelf life
- test product was tested without dilution, as provided by the sponsor. Three untreated negative control skin tissue samples were exposed for 24 hours.
- Triton X-100 (lot no. 082615BBA), a positive control, was used to expose one tissue sample for 1 hour, the second tissue sample for 4 hours, and the third tissue sample for 24 hours. .
- an MTT control evaluation was conducted, which considered the value as a result of the direct reduction of the product of MTT.
- the test product directly reduced MTT. Frozen tissue was exposed to the test article to determine whether the test article was effectively washed from the tissue during the test procedure.
- results from frozen tissues indicate that the test product was washed away from the tissues, indicating that the results are valid.
- the absorbance of the sample is set to 570nm with a number of isopropyl alcohol 200 ⁇ m aliquot VERSA max TM It was determined using a tunable microplate reader Tunable Microplate Reader (with SOFTmax PRO r Software).
- SOFTmax ® PRO Software converted the absorbance values to the probabilistic viability of tissue culture. These numbers showed that over time, by the SOFTmax PRO Software r, since the ET-50 was determined by interpolation. The ET-50 is the estimated time when an organization's probability of practicability drops to 50%.
- Non-Irrit. Non-Irritation
- Test Product # 1 Determination It was 343.39 hours associated with ET-50, a non-irritant classification for the test product, which was confirmed from the skin irritation test results for the test product in Table 8 below.
- HIV-1 human immunodeficiency virus
- cell line Mn cell line Mn; ZeptoMetrix, Corp. # 0810027CF
- Cytotoxicity and antiviral experiments were repeated twice each.
- the characterization of the identity, strength, purity, composition, stability and solubility of the test product is the responsibility of the sponsor of the study, except that it has not been conducted by the laboratory (GLP 58.105).
- Good Laboratory Practices were followed.
- One deviation from the study protocol occurred during the evaluation process.
- the volume of experimental product and virus to be evaluated was changed. The difference is intentional and did not have any negative effects on the study results. No deviation was found from the applicable BSLI Standard Operating Procedures.
- the experimental product was provided to the laboratory by a research sponsor. In addition to preservation of the experimental product, the responsibility for determining the identity, strength, purity, composition, stability and solubility of the experimental product was placed on the research sponsor. Description of the experimental product is as follows.
- H1V-1 cell line Mn (ZeptoMetrix, Corp. # 0810027CF)
- Host cell C8166 (human T cell leukemia [ECACC # 88051601])
- CPE cytopathic effect
- MTT cell proliferation assay
- MTT 5-diphenyltetrazolium bromide
- the antiviral experiment was carried out as follows.
- Table 9 summarizes the inhibitory and cytotoxic concentrations for HIV-1 cell line Mn.
- Table 12 below and FIG. 4 attached below calculate a graph pad prism for the presence of C8166 cell concentration.
- Scope In this study, the virucidal properties of one experimental product were evaluated in an immunogenicity test against HIV-1 cell line Mn using the In-Vitro Time-Kill method. The experimental product was evaluated at a final concentration of 90% (v / v). Plating was repeated four times. 50% tissue culture infectious dose (TCID50) assay-Quantal test (Spearman-Karber Method). Percent and log 10 reductions from the initial population were determined following exposure of the viral cell lines to the experimental product for 30 and 60 seconds.
- TCID50 tissue culture infectious dose
- the research protocol details the research methodology, as presented in Addendum 3 in the General Data Gathering Form (Form No. 91-L-002). One deviation from the methodology described in the study protocol occurred during this evaluation process. Protocol and / or SOP Deviation Recording Form [Form No. 99-QA-004]. No deviation from the applicable Standard Operating Procedure occurred during this evaluation.
- the evaluated experimental product was provided to the laboratory by the research sponsor. In addition to preservation of the experimental product, the responsibility for determining the identity, strength, purity, composition, stability and solubility of the experimental product was placed on the research sponsor.
- HIV-1 human immunodeficiency virus
- cell line Mn cell line Mn; ZeptoMetrix, Corp. # 0810027CF
- Host cell C8166 (Human T cell leukemia [ECACC # 88051601])
- GM growth medium
- MM retention medium
- Experimental virus preparation The experimental virus used in this study was prepared from BSLI high titer virus stock. On the day of use, an aliquot of the stock was removed from the -70 ° C refrigerator and thawed before use in the experiment.
- Table 13 below provides data from viral infectivity control (TCID 50 ) and post-exposure infectivity (TCID 50 ); LOG 10 and percent reductions were observed with 30 and 60 seconds of exposure to HIV-1 in the test product.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (13)
- 정제수(Aqua) 65 내지 79.89 wt%에 부틸렌글라이콜(Butylene Glycol) 12 내지 18 wt%, 글리세린(Glycerin) 7 내지 13 wt%, 첨가제 1.11 내지 5.85 wt%를 혼합하고, 상기 첨가제는 소듐폴리아크릴레이트(Sodium Polyacrylate), 촉매제, 카보머(Carbomer), 무기담체, 금속염, 은 전구체(前驅體), 시트릭애씨드(Citric Acid), 하이드록시에칠셀룰로오스(hidroxyethylcellulose)를 포함하여 구성하는 것을 특징으로 하는 소취용 화장품 조성물.
- 제 1 항에 있어서,상기 첨가제 중에서,상기 소듐폴리아크릴레이트는 1 내지 4 wt%의 비율로 혼합 구성하고,상기 촉매제는 0.01 내지 0.30 wt%의 비율로 혼합 구성하고,상기 카보머는 0.01 내지 0.30 wt%의 비율로 혼합 구성하고,상기 무기담체는 0.01 내지 0.30 wt%의 비율로 혼합 구성하고,상기 금속염은 0.01 내지 0.30 wt%의 비율로 혼합 구성하고,상기 은 전구체는 0.05 내지 0.30 wt%의 비율로 혼합 구성하고,상기 시트릭애씨드는 0.01 내지 0.05 wt%의 비율로 혼합 구성하고,상기 하이드록시에칠셀룰로오스는 0.01 내지 0.30 wt%의 비율로 혼합 구성하는 것을 특징으로 하는 소취용 화장품 조성물.
- 제 2 항에 있어서, 상기 촉매제는 암모니아수, 탄산수소암모늄, 트리에탄올아민(Triethanolamine)으로 이루어진 군으로부터 적어도 어느 하나가 선택 사용되는 것을 특징으로 하는 소취용 화장품 조성물.
- 제 2 항에 있어서,상기 무기담체는 100 내지 150㎚의 평균 입경을 가지는 실리카(Silica), 제오라이트(Zeolite), 지류코늄(Zirconium)으로 이루어진 군으로부터 적어도 어느 하나가 선택 사용되는 것을 특징으로 하는 소취용 화장품 조성물.
- 제 2 항에 있어서, 상기 금속염은 금속의 질산염, 인산염 및 탄산염으로 이루어지는 군으로부터 적어도 어느 하나가 선택 사용되는 것을 특징으로 하는 소취용 화장품 조성물.
- 제 2 항에 있어서, 상기 은 전구체는 질산은, 아질산은, 과염소산은으로 이루어지는 군으로부터 적어도 어느 하나가 선택 사용되는 것을 특징으로 하는 소취용 화장품 조성물.
- (a) 정제수(Aqua) 65 내지 79.89 wt%에 대하여, 부틸렌글라이콜(Butylene Glycol) 12 내지 18 wt%를 1차 혼합하는 단계;(b) 상기 (a)단계의 1차 혼합물에 항균 및 항바이러스와 소취용의 유효성분을 포함하는 첨가제로서, 소듐폴리아크릴레이트 1 내지 4 wt%, 촉매제 0.01 내지 0.30 wt%, 카보머 0.01 내지 0.30 wt%, 무기담체 0.01 내지 0.30 wt%, 금속염 0.01 내지 0.30 wt%, 은 전구체 0.05 내지 0.30 wt%, 시트릭애씨드 0.01 내지 0.05 wt%, 하이드록시에칠셀룰로오스는 0.01 내지 0.30 wt%를 2차 혼합하되, 상기 금속염과 은 전구체는 환원제를 첨가하여 35 내지 38℃의 온도범위에서 3 내지 4시간 동안 반응시켜 상기 무기담체의 표면상에 결합층을 형성하는 단계; 및,(c) 상기 (b)단계의 2차 혼합물에 분산용매로서 글리세린(Glycerin) 7 내지 13 wt%를 2차 혼합하면서 100 내지 500 rpm의 속도로 분산시켜, 항균 및 항바이러스와 소취용의 특성을 가지면서 신체의 중요부위에 도포되는 클린젤 조성물을 완성하는 단계; 를 포함하여 진행하는 것을 특징으로 하는 소취용 화장품 조성물 제조방법.
- 제 7 항에 있어서, 상기 환원제는 아스코르브산 또는 소듐보로하이드라이드로서, 상기 클린젤 복합체 100중량부에 대하여 0.1 내지 0.5중량부를 사용하는 것을 특징으로 하는 소취용 화장품 조성물 제조방법.
- 제 7 항에 있어서,상기 첨가제 중에서,상기 소듐폴리아크릴레이트는 1 내지 4 wt%의 비율로 혼합하고,상기 촉매제는 0.01 내지 0.30 wt%의 비율로 혼합하고,상기 카보머는 0.01 내지 0.30 wt%의 비율로 혼합하고,상기 무기담체는 0.01 내지 0.30 wt%의 비율로 혼합하고,상기 금속염은 0.01 내지 0.30 wt%의 비율로 혼합하고,상기 은 전구체는 0.05 내지 0.30 wt%의 비율로 혼합하고,상기 시트릭애씨드는 0.01 내지 0.05 wt%의 비율로 혼합하고,상기 하이드록시에칠셀룰로오스는 0.01 내지 0.30 wt%의 비율로 혼합하는 것을 특징으로 하는 소취용 화장품 조성물 제조방법.
- 제 9 항에 있어서,상기 촉매제는 암모니아수, 탄산수소암모늄, 트리에탄올아민(Triethanolamine)으로 이루어진 군으로부터 적어도 어느 하나가 선택 사용되는 것을 특징으로 하는 소취용 화장품 조성물 제조방법.
- 제 9 항에 있어서,상기 무기담체는 100 내지 150㎚의 평균 입경을 가지는 실리카(Silica), 제오라이트(Zeolite), 지류코늄(Zirconium)으로 이루어진 군으로부터 적어도 어느 하나가 선택 사용되는 것을 특징으로 하는 소취용 화장품 조성물 제조방법.
- 제 9 항에 있어서, 상기 금속염은 금속의 질산염, 인산염 및 탄산염으로 이루어지는 군으로부터 적어도 어느 하나가 선택 사용되는 것을 특징으로 하는 소취용 화장품 조성물 제조방법.
- 제 9 항에 있어서, 상기 은 전구체는 질산은, 아질산은, 과염소산은으로 이루어지는 군으로부터 적어도 어느 하나가 선택 사용되는 것을 특징으로 하는 소취용 화장품 조성물 제조방법.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16873195.8A EP3388049A4 (en) | 2015-12-09 | 2016-08-18 | COSMETIC DEODORIZING COMPOSITION AND METHOD FOR PREPARING THE SAME |
US16/060,934 US20190070081A1 (en) | 2015-12-09 | 2016-08-18 | Deodorizing cosmetic composition and method for preparing same |
CN201680072323.9A CN108430438A (zh) | 2015-12-09 | 2016-08-18 | 除臭用化妆品组合物及其制备方法 |
JP2018550312A JP2018537542A (ja) | 2015-12-09 | 2016-08-18 | 消臭用化粧品組成物及びその製造方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150175069A KR101666196B1 (ko) | 2015-12-09 | 2015-12-09 | 소취용 화장품 조성물 및 그 제조방법 |
KR10-2015-0175069 | 2015-12-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017099329A1 true WO2017099329A1 (ko) | 2017-06-15 |
Family
ID=57157006
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2016/009071 WO2017099329A1 (ko) | 2015-12-09 | 2016-08-18 | 소취용 화장품 조성물 및 그 제조방법 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20190070081A1 (ko) |
EP (1) | EP3388049A4 (ko) |
JP (1) | JP2018537542A (ko) |
KR (1) | KR101666196B1 (ko) |
CN (1) | CN108430438A (ko) |
WO (1) | WO2017099329A1 (ko) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180081992A (ko) * | 2017-01-09 | 2018-07-18 | (주)아인스코퍼레이션 | 겔 타입의 도포제가 충진되는 남성용 피임기구 |
CN111514043A (zh) * | 2019-05-31 | 2020-08-11 | 南开大学 | 一种治疗臭汗症的制剂,及其制备方法 |
CN113476396A (zh) * | 2021-06-15 | 2021-10-08 | 四川滋兴生物科技有限公司 | 一种抗hpv凝胶及其生产工艺 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002508763A (ja) * | 1997-06-23 | 2002-03-19 | ザ、プロクター、エンド、ギャンブル、カンパニー | 無水ゲル状脱臭組成物 |
JP2007223995A (ja) * | 2006-02-27 | 2007-09-06 | Shiseido Co Ltd | 消臭用組成物 |
KR20100103515A (ko) * | 2007-12-14 | 2010-09-27 | 킴벌리-클라크 월드와이드, 인크. | 피부 청결 및 건강 향상용 배합물 및 제품 |
US20100254926A1 (en) * | 2007-10-01 | 2010-10-07 | Colgate- Palmolive Company | Propylene Glycol/Glycerin-Based Deodorant |
KR20140041476A (ko) * | 2011-04-04 | 2014-04-04 | 엔비론 스킨 케어 (프로프리에타리) 리미티드 | 바이러스 감염의 치료 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3156481B2 (ja) * | 1993-12-28 | 2001-04-16 | 松下電器産業株式会社 | 抗菌性スプレー |
JP4235849B2 (ja) * | 1994-07-19 | 2009-03-11 | シナネン株式会社 | 耐変色性及び分散性に優れた防臭化粧料 |
DE19843140C1 (de) * | 1998-09-21 | 1999-10-07 | Mdle Medical Device Lab Europ | Vorrichtung zur Pflege von Kontaktlinsen |
KR20010038672A (ko) | 1999-10-26 | 2001-05-15 | 송기태 | 조루방지 및 음경확대 콘돔 |
JP4274354B2 (ja) * | 2003-04-04 | 2009-06-03 | 株式会社資生堂 | 皮膚外用剤 |
WO2004037220A1 (ja) * | 2002-10-25 | 2004-05-06 | Shiseido Company, Ltd. | 皮膚外用剤 |
JP2004143104A (ja) * | 2002-10-25 | 2004-05-20 | Shiseido Co Ltd | 皮膚外用剤 |
GB0300808D0 (en) | 2003-01-14 | 2003-02-12 | Unilever Plc | Home and personal care compositions with lubricants |
WO2007099738A1 (ja) * | 2006-02-27 | 2007-09-07 | Shiseido Company, Ltd. | 消臭用組成物 |
US20090197892A1 (en) * | 2007-08-21 | 2009-08-06 | Nawaz Ahmad | Anhydrous compositions useful for attaining enhanced sexual wellness |
KR20080030981A (ko) * | 2008-03-17 | 2008-04-07 | (주)에이씨티 | 항균력을 갖는 나노실버가 코팅된 실리카 분말 및 분산액의화장료용 조성물. |
CN104771791A (zh) * | 2014-01-10 | 2015-07-15 | 贵州金玖生物技术有限公司 | 一种水溶性无菌医用多功能润滑剂配方及其制备方法 |
CN103908473B (zh) * | 2014-03-28 | 2016-08-17 | 长沙迪谷纳米生物科技有限公司 | 治疗和预防妇女子宫颈癌的纳米银抗癌组合物的应用 |
CN104922110A (zh) * | 2015-07-14 | 2015-09-23 | 江南大学 | 一种可避孕且可预防性病和艾滋病传染的组合物 |
-
2015
- 2015-12-09 KR KR1020150175069A patent/KR101666196B1/ko active IP Right Grant
-
2016
- 2016-08-18 JP JP2018550312A patent/JP2018537542A/ja active Pending
- 2016-08-18 CN CN201680072323.9A patent/CN108430438A/zh active Pending
- 2016-08-18 EP EP16873195.8A patent/EP3388049A4/en not_active Withdrawn
- 2016-08-18 US US16/060,934 patent/US20190070081A1/en not_active Abandoned
- 2016-08-18 WO PCT/KR2016/009071 patent/WO2017099329A1/ko active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002508763A (ja) * | 1997-06-23 | 2002-03-19 | ザ、プロクター、エンド、ギャンブル、カンパニー | 無水ゲル状脱臭組成物 |
JP2007223995A (ja) * | 2006-02-27 | 2007-09-06 | Shiseido Co Ltd | 消臭用組成物 |
US20100254926A1 (en) * | 2007-10-01 | 2010-10-07 | Colgate- Palmolive Company | Propylene Glycol/Glycerin-Based Deodorant |
KR20100103515A (ko) * | 2007-12-14 | 2010-09-27 | 킴벌리-클라크 월드와이드, 인크. | 피부 청결 및 건강 향상용 배합물 및 제품 |
KR20140041476A (ko) * | 2011-04-04 | 2014-04-04 | 엔비론 스킨 케어 (프로프리에타리) 리미티드 | 바이러스 감염의 치료 |
Also Published As
Publication number | Publication date |
---|---|
US20190070081A1 (en) | 2019-03-07 |
EP3388049A1 (en) | 2018-10-17 |
EP3388049A4 (en) | 2019-06-19 |
CN108430438A (zh) | 2018-08-21 |
KR101666196B1 (ko) | 2016-10-14 |
JP2018537542A (ja) | 2018-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5545401A (en) | Antiviral, spermicidal vaginal gel and foam containing low molecular weight povidone-iodine | |
WO2017099329A1 (ko) | 소취용 화장품 조성물 및 그 제조방법 | |
Garg et al. | Studies on the contraceptive efficacy of Praneem polyherbal cream | |
US5387611A (en) | Use of butylurea, nonoxynol-9 and benzalkonium chloride as anti-bacterial, anti-viral contraceptive agents | |
EP0576425B1 (en) | Method for inactivating sperm | |
WO2018128212A1 (ko) | 겔 타입의 도포제가 충진되는 남성용 피임기구 | |
US6028115A (en) | Method for preventing sexually transmitted diseases | |
US20020151521A1 (en) | Universal antiviral composition | |
US5925621A (en) | Method for preventing sexually transmitted diseases | |
US20050037033A1 (en) | Microbicidal compositions and methods and use | |
US20010053378A1 (en) | Antiviral fumaric acid composition | |
US6696071B2 (en) | Pre-coital and post-coital rinse with anti-viral and skin-protective zinc salts | |
EP0402078A3 (en) | Sexual lubricants containing zinc as an anti-viral agent | |
CA1326446C (en) | Substance or pharmaceutical or cosmetic composition inhibition or destroying at least one unicellular living creature and/or at least one virus, drug or product containing such a substance, process of manufacture of such substance, chemical compound included in such substance, and process of inhibition or destruction of at least one... | |
US5932619A (en) | Method for preventing sexually transmitted diseases | |
US5646189A (en) | Prevention of HIV infection | |
US6302108B1 (en) | Spermicidal and viricidal compositions | |
WO2011087494A2 (en) | Use of a virucidal preparation on an area of the face for prevention of transmission or contraction of viral illnesses, or to shorten the duration of, or lessen the severity of viral illnesses | |
WO2020054937A1 (ko) | 식물성 키토산을 이용한 여성용 청결제 조성물, 이의 제조방법 및 이를 포함하는 여성용 청결제 | |
Piret et al. | Subchronic (26‐and 52‐week) toxicity and irritation studies of a novel microbicidal gel formulation containing sodium lauryl sulfate in animal models | |
US20090118352A1 (en) | Broad spectrum microbicidal and spermicidal compositions and methods | |
US20050025847A1 (en) | Microbicidal compositions and method of use | |
CN1135978C (zh) | 性润舒膏 | |
EP3595726B1 (en) | Treatment of herpes simplex symptoms on skin and mucous membrane of mammals | |
WO2000072839A1 (en) | Antiseptic spermicidal composition and means for its application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16873195 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2018550312 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2016873195 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2016873195 Country of ref document: EP Effective date: 20180709 |